APA (7th ed.) Citation

Strober, B., Armstrong, A., Rubant, S., Patel, M., Wu, T., Photowala, H., & Crowley, J. (2022). Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal of Dermatological Treatment, 33(7), 2991. https://doi.org/10.1080/09546634.2022.2095328

Chicago Style (17th ed.) Citation

Strober, Bruce, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu, Huzefa Photowala, and Jeffrey Crowley. "Switching to Risankizumab from Ustekinumab or Adalimumab in Plaque Psoriasis Patients Improves PASI and DLQI Outcomes for Sub-optimal Responders." Journal of Dermatological Treatment 33, no. 7 (2022): 2991. https://doi.org/10.1080/09546634.2022.2095328.

MLA (9th ed.) Citation

Strober, Bruce, et al. "Switching to Risankizumab from Ustekinumab or Adalimumab in Plaque Psoriasis Patients Improves PASI and DLQI Outcomes for Sub-optimal Responders." Journal of Dermatological Treatment, vol. 33, no. 7, 2022, p. 2991, https://doi.org/10.1080/09546634.2022.2095328.